Results 201 to 210 of about 75,992 (272)

Nivolumab-induced folliculitis: A case of immune-related cutaneous adverse reaction.

Indian J Pharmacol
Sankar PA, Prabha N.
europepmc   +1 more source

Checkpoint Inhibitor-Induced Raynaud's Phenomenon, Hypothyroidism, and Pneumonitis in Head and Neck Cancer: A Case Report. [PDF]

Cureus
Bodoki L, Csonka T, Szekanecz Z, Szamosi S, Major NA, Szekanecz É.   +5 more
europepmc   +1 more source

Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report

Respirology Case Reports, Volume 14, Issue 7, July 2026.
We report a fatal case of acute TLS following a single 1‐mg dose of tarlatamab in a patient with relapsed SCLC with extensive liver metastases. This case highlights the importance of TLS risk assessment prior to tarlatamab treatment. Extensive liver metastases and elevated lactate dehydrogenase levels may be risk factors for TLS in patients with SCLC ...
Katsuhiko Shibata, Hiromu Tanaka, Yusuke Arai, Yusuke Watanuki, Takashi Kokubo, Yo Watanabe, Shingo Nakayama, Takahiro Asami, Takashi Inoue   +8 more
wiley   +1 more source

Correction: Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors. [PDF]

Front Immunol
Alsaafeen BH, Ali BR, Elkord E.
europepmc   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 1, Page 103-111, July 2026.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source

A Case of Concurrent Autoimmune Thyroiditis and Adrenal Insufficiency Following Nivolumab Therapy for Advanced Renal Cell Carcinoma. [PDF]

Cureus
Dooley GD, Li H, Agomuoh I, Al-Saghir F, Arsene C.   +4 more
europepmc   +1 more source

Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
ABSTRACT Although tislelizumab is approved across multiple malignancies and dosing schedules, intravenous administration imposes logistical burdens. A subcutaneous formulation may improve convenience and reduce resource demands if comparable exposure is achieved. This study evaluated the pharmacokinetics, bioavailability, and injection‐site performance
Xiangyu Liu, Ye Guan, Yixi Liu, Tian Yu, Ramil Abdrashitov, Ziru Niu, Xiao Lin, Xiaohan Ye, Yutong Wang, Srikumar Sahasranaman, William D. Hanley, Nageshwar Budha   +11 more
wiley   +1 more source

Clinical Impact of Nivolumab in Sinonasal Mucosal Melanoma: A 14-Year Single-Center Retrospective Study and Comprehensive Literature Review. [PDF]

Cancers (Basel)
Terazawa K, Utakata R, Iinuma R, Kuroki M, Yamada T, Ishihara H, Kawaura R, Okuda H, Mori K, Shibata H, Obara N, Umeda M, Ikeda R, Saijo K, Ogawa T.   +14 more
europepmc   +1 more source

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, Volume 65, Issue 7, Page 1376-1382, July 2026.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source